Navigation Links
Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
Date:9/10/2008

xiety, stress and fear, he said. Scientists have implicated an excessive stress response to a wide array of disorders, from ADHD and Tourette's syndrome to post-traumatic stress disorder and migraines.

Addrenex is currently developing a cadre of drugs focused on treating these and other conditions arising from adrenergic excess, including hypertension, menopausal flushing, pain and sleep disturbance. By mining a library of 400 adrenergic compounds at the University of Nebraska Medical Center, Addrenex scientists have already identified one new drug candidate, a compound code named ADX415, to treat hypertension and other conditions.

"With the extremely positive data from our first study, we are well under way toward our goal of regulating adrenergic excess and helping to ameliorate medical conditions that arise from this physiologic imbalance," said Khayrallah.

The company is also midway through a second ADHD clinical trial testing the effects of Clonicel together with stimulants. The goal is to determine if the two treatments together alleviate a broader range of symptoms than either drug alone.


'/>"/>
SOURCE Addrenex
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
2. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
3. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
4. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
5. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
6. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
9. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
10. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)...., Nov. 19 Amgen,(Nasda...mpany, a subsidiary of,Takeda Pharmaceutical Comp...ollment in the Phase 3 MONET1 trial evaluating mot...nd carboplatin for the first-line treatment of,ad... temporarily suspended,following a planned safety...
(Date:11/19/2008)...Nov. 19 Biotech scientists increas...logy research to better understand the effects of ...s, reports Genetic Engineering & Biotechnolog... figuring out a new compound,s mechanism of action... technique, according to the November 15 issue of ...
(Date:11/18/2008)... NeuroDiscovery Ltd (ASX:...and drug development Company,and Sosei Group Cor...ding,international biopharmaceutical company, tod...ther pivotal pre-clinical efficacy data for NSL-04... therapy for neuropathic pain and has,successfull...
(Date:11/18/2008)... 18 Forty-two leading U...mber national forum to consider cutting-edge innov... national economy from outbreaks of dangerous zoon... , Among those innovations: , , , ...hen table that detects highly contagious and dange...
Breaking Medicine Technology:Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7GEN Reports on the Trend Toward Predictive Toxicogenomics 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2International Aid Named as a MinistryWatch com Shining Light Christian Ministry 8404 1International Aid Named as a MinistryWatch com Shining Light Christian Ministry 8404 2IQS Donates Quality Management Software to Family Health International 8402 1IQS Donates Quality Management Software to Family Health International 8402 2IQS Donates Quality Management Software to Family Health International 8402 3Genome Technology Magazine Names Top Young Investigators of 2007 2246 1Genome Technology Magazine Names Top Young Investigators of 2007 2246 2Robin C Stracey Joins Cantimer Inc as President and CEO 2244 1Robin C Stracey Joins Cantimer Inc as President and CEO 2244 2
...novative technology has enabled more and more labo...ns office, the central laboratory is hardly threat... that medium and large labs are busier than ever b...old standard reliability and ability to handle ver...nd pivotal position in the clinical landscape. ,...
...rus (EBV), which causes infectious mononucleosis (...occurs worldwide, and most people become infected ...d States, as many as 95 percent of adults between ... developed countries, including the U.S., infectio... young adulthood, causing infectious mononucleosis...
Other Medicine Technology:When Volume Matters, Immunoassay Systems Deliver 2When Volume Matters, Immunoassay Systems Deliver 3Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies 2Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies 3
(Date:11/21/2008)...Nov. 21 The Providence S...ced that Craig A. Norris, the Company,s,Chief Ope...s Board of,Directors. Mr. Norris, appointment fi...n of Steven I. Geringer and returns the board to s...mittee of the Board. , Mr. Norris, age 41, ...
(Date:11/21/2008)...anzel proved effective against Lennox-Gastaut synd...) -- A new drug called Banzel (rufinamide) has bee...re form of epilepsy called Lennox-Gastaut syndrome...Friday. , The approval was based on results of ... ages 4 to 30. Compared to patients who took a pla...
(Date:11/21/2008)...a., Nov. 21 New researc...er a smokeless, spitless tobacco product aimed at ...ave found that RJ Reynolds, Camel Snus - touted as...contains surprisingly high levels of nicotine. , ...st other snuff products," said Bruce Adkins of the...
(Date:11/21/2008)... Nov. 21 U.S. News &...ity Assurance (NCQA) ranked BlueChoice(R) HealthPl... Best Health Plans(TM), published in U.S. News &am...respected annual ranking ranks the nation,s best h...sfaction and NCQA accreditation scores. NCQA and U...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2
...ore has announced that it will be shortly implemen...cted with bird flu can be immediately isolated. //...ergency vaccination program should the threat of b...nfecting facilities and restricted entry are alrea...
...d obesity rates are soaring as well.Studies say th...he world by the end of the decade and raise the ri...2010 the number of overweight and obese youngsters...would be 26 million. Over a million children will...
... urban Ontario and followed over two years, resear...nizations. //Dr. Astrid Guttmann, lead author of t...ciences (ICES) said that the overall visit rates t...t was later found that the mothers of the kids vis...
...ed of bird flu, Hong Kong banned the imports of li... The man is believed to have contracted the virus ...e bordering Hong Kong and one of the territory's m...d Thursday, nine days after being hospitalised aft...
Other Medicine News:Health News:Vaccination Schedules Rates among Canadian Kids Dip Low 2
For Tricuspid Mapping. Biosense Webster offers a complete line of specialty 20-pole catheters for mapping in the atrium. The HALO XP 20-pole deflectable catheter is designed for simple placement and
...sense Webster is the source for a complete line of...d mapping - all with the quality, reliability and ... leader in catheter technology. All of our coronar...nstructed to help minimize the frustration and exc...
The reliable, easy-to-steer Bart EPXT catheter offers an exceptional blend of shaft stability and curve control for faster, more accurate mapping. Bard's exclusive point-of-tip actuation control supp
Sophisticated DecaPolar Catheters provide enhanced recording and mapping quality.
Medicine Products: